Cargando…
Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection
OBJECTIVE: This study aimed to analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for locoregional recurrent pancreatic cancer after radical resection. METHODS: Patients with locoregional recurrent pancreatic cancer after surgery treated with SBRT in our institution were retr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353056/ https://www.ncbi.nlm.nih.gov/pubmed/35936670 http://dx.doi.org/10.3389/fonc.2022.925043 |
_version_ | 1784762790408355840 |
---|---|
author | Ji, Xiaoqin Zhou, Bin Ding, Wei Wang, Jiasheng Jiang, Wanrong Li, Yikun Hu, Jun Sun, Xiangdong |
author_facet | Ji, Xiaoqin Zhou, Bin Ding, Wei Wang, Jiasheng Jiang, Wanrong Li, Yikun Hu, Jun Sun, Xiangdong |
author_sort | Ji, Xiaoqin |
collection | PubMed |
description | OBJECTIVE: This study aimed to analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for locoregional recurrent pancreatic cancer after radical resection. METHODS: Patients with locoregional recurrent pancreatic cancer after surgery treated with SBRT in our institution were retrospectively investigated from January 2010 to January 2020. Absolute neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) recorded at pretreatment were analyzed. Endpoints included overall survival (OS), progression-free survival (PFS) and cumulative incidences of local failure (LF) and metastatic failure (MF). RESULTS: A total of 22 patients received SBRT with a median prescribed dose of 40 Gy (range of 30-50 Gy)/4 to 7 fractions. The median OS of all patients was 13.6 months (95% CI, 9.6-17.5 months). 0-1 performance status (HR 12.10, 95% CI 2.04-71.81, P=0.006) and ≤2.1 pre-SBRT NLR (HR 4.05, 95% CI 1.21-13.59, P=0.023) were significant predictors of higher OS on multivariable analysis. The median progression-free survival (PFS) of the cohort was 7.5 months (95% CI, 6.5-8.5 months). The median time to LF and MF were 15.6 months and 6.4 months, respectively. The rate of MF as a first event was higher than that of first event LF. Pain relief was observed in all patients (100%) 6 weeks after SBRT. In terms of acute toxicity, grade 1 including fatigue (6, 27.3%), anorexia (6, 27.3%), nausea (4, 18.2%) and leukopenia (4, 18.2%) was often observed. No acute toxicity of grade 4 or 5 was observed. In terms of late toxicity, no treatment-related toxicity was found during follow-up. CONCLUSION: This study showed that SBRT can significantly reduce pain, effectively control local tumor progression, and have acceptable toxicity for patients with locoregional recurrence after radical resection of primary pancreatic cancer. Good performance status and lower pre-SBRT NLR were associated with improved overall survival. |
format | Online Article Text |
id | pubmed-9353056 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93530562022-08-06 Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection Ji, Xiaoqin Zhou, Bin Ding, Wei Wang, Jiasheng Jiang, Wanrong Li, Yikun Hu, Jun Sun, Xiangdong Front Oncol Oncology OBJECTIVE: This study aimed to analyze the efficacy and toxicity of stereotactic body radiotherapy (SBRT) for locoregional recurrent pancreatic cancer after radical resection. METHODS: Patients with locoregional recurrent pancreatic cancer after surgery treated with SBRT in our institution were retrospectively investigated from January 2010 to January 2020. Absolute neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) recorded at pretreatment were analyzed. Endpoints included overall survival (OS), progression-free survival (PFS) and cumulative incidences of local failure (LF) and metastatic failure (MF). RESULTS: A total of 22 patients received SBRT with a median prescribed dose of 40 Gy (range of 30-50 Gy)/4 to 7 fractions. The median OS of all patients was 13.6 months (95% CI, 9.6-17.5 months). 0-1 performance status (HR 12.10, 95% CI 2.04-71.81, P=0.006) and ≤2.1 pre-SBRT NLR (HR 4.05, 95% CI 1.21-13.59, P=0.023) were significant predictors of higher OS on multivariable analysis. The median progression-free survival (PFS) of the cohort was 7.5 months (95% CI, 6.5-8.5 months). The median time to LF and MF were 15.6 months and 6.4 months, respectively. The rate of MF as a first event was higher than that of first event LF. Pain relief was observed in all patients (100%) 6 weeks after SBRT. In terms of acute toxicity, grade 1 including fatigue (6, 27.3%), anorexia (6, 27.3%), nausea (4, 18.2%) and leukopenia (4, 18.2%) was often observed. No acute toxicity of grade 4 or 5 was observed. In terms of late toxicity, no treatment-related toxicity was found during follow-up. CONCLUSION: This study showed that SBRT can significantly reduce pain, effectively control local tumor progression, and have acceptable toxicity for patients with locoregional recurrence after radical resection of primary pancreatic cancer. Good performance status and lower pre-SBRT NLR were associated with improved overall survival. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353056/ /pubmed/35936670 http://dx.doi.org/10.3389/fonc.2022.925043 Text en Copyright © 2022 Ji, Zhou, Ding, Wang, Jiang, Li, Hu and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Ji, Xiaoqin Zhou, Bin Ding, Wei Wang, Jiasheng Jiang, Wanrong Li, Yikun Hu, Jun Sun, Xiangdong Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection |
title | Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection |
title_full | Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection |
title_fullStr | Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection |
title_full_unstemmed | Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection |
title_short | Efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection |
title_sort | efficacy of stereotactic body radiation therapy for locoregional recurrent pancreatic cancer after radical resection |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353056/ https://www.ncbi.nlm.nih.gov/pubmed/35936670 http://dx.doi.org/10.3389/fonc.2022.925043 |
work_keys_str_mv | AT jixiaoqin efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection AT zhoubin efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection AT dingwei efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection AT wangjiasheng efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection AT jiangwanrong efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection AT liyikun efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection AT hujun efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection AT sunxiangdong efficacyofstereotacticbodyradiationtherapyforlocoregionalrecurrentpancreaticcancerafterradicalresection |